# Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

> **NCT00002866** · PHASE1 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer
- Neutropenia

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** docetaxel
- **DRUG:** epirubicin hydrochloride

## Key facts

- **NCT ID:** NCT00002866
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-08-12
- **Primary completion:** 2005-07-19
- **Final completion:** 2009-12-21
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002866, "Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00002866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*